The DOI matches its Crossref record; 691 of the 691 references it cites were found in a registry or an index.
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Surfactants and interfacial phenomena
(2005) · Choice Reviews Online · doi:10.5860/choice.42-2832 · Cited by 5,395
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,978
Determining the Size and Shape Dependence of Gold Nanoparticle Uptake into Mammalian Cells
Chithrani, B. D., Ghazani, A. A., & Chan, W. C. W. (2006) · Nano Letters · doi:10.1021/nl052396o · Cited by 4,879
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 15×
“Through experimentation with PEG polymers of different sizes (350–15000 Da) and some consideration regarding the metabolism of PEGylated lipids and their kidney excretion rate, a 2000 Da PEG residue was the polymer of choice for the development of Doxil (Barenholz, 2012b).”
BackgroundMethodInfluentialDiffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664 · cited 4×
“For these particles, the spherical shape is not induced by the preparative procedure but is a result of the electrostatic interaction between the polar or ionogenic phospholipid head group and the solvent medium and the nature of nonpolar lipid hydrocarbon moieties in the solvent (Bangham et al., 1965; Lasic, 1982).”
BackgroundInfluentialSchafer, F. Q., & Buettner, G. R. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00480-4 · Cited by 4,587
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Cited by
Design of liposomes as drug delivery system for therapeutic applications
Guimarães, D., Cavaco-Paulo, A., & Nogueira, E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120571 · Cited by 1,196
Optical Properties and Applications of Plasmonic‐Metal Nanoparticles
Wang, L., Hasanzadeh Kafshgari, M., & Meunier, M. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202005400 · Cited by 630
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Composition design and medical application of liposomes
Li, M., Du, C., Guo, N., Teng, Y., Meng, X., Sun, H., Li, S., Yu, P., & Galons, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.007 · Cited by 555
Lipid Nanoparticles for Drug Delivery
Xu, L., Wang, X., Liu, Y., Yang, G., Falconer, R. J., & Zhao, C.-X. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100109 · Cited by 545
Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment
García-Pinel, B., Porras-Alcalá, C., Ortega-Rodríguez, A., Sarabia, F., Prados, J., Melguizo, C., & López-Romero, J. M. (2019) · Nanomaterials · doi:10.3390/nano9040638 · Cited by 527
Nanomedicine review: clinical developments in liposomal applications
Beltrán-Gracia, E., López-Camacho, A., Higuera-Ciapara, I., Velázquez-Fernández, J. B., & Vallejo-Cardona, A. A. (2019) · Cancer Nanotechnology · doi:10.1186/s12645-019-0055-y · Cited by 513
Sahu, T., Ratre, Y. K., Chauhan, S., Bhaskar, L. V. K. S., Nair, M. P., & Verma, H. K. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102487 · Cited by 487
Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agents
Hashem, S., Ali, T. A., Akhtar, S., Nisar, S., Sageena, G., Ali, S., Al-Mannai, S., Therachiyil, L., Mir, R., Elfaki, I., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113054 · Cited by 377
Bellavia, D., Raimondo, S., Calabrese, G., Forte, S., Cristaldi, M., Patinella, A., Memeo, L., Manno, M., Raccosta, S., Diana, P., et al. (2017) · Theranostics · doi:10.7150/thno.17092 · Cited by 368
Advancement of the emerging field of RNA nanotechnology
Jasinski, D., Haque, F., Binzel, D. W., & Guo, P. (2017) · ACS Nano · doi:10.1021/acsnano.6b05737 · Cited by 352
The role of liposomes in clinical nanomedicine development. What now? Now what?
Crommelin, D. J. A., van Hoogevest, P., & Storm, G. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.023 · Cited by 349
Maeki, M., Kimura, N., Sato, Y., Harashima, H., & Tokeshi, M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.03.008 · Cited by 319
Liposome-based drug co-delivery systems in cancer cells
Zununi Vahed, S., Salehi, R., Davaran, S., & Sharifi, S. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.11.073 · Cited by 307
Emerging role of exosomes in cancer therapy: progress and challenges
Li, J., Wang, J., & Chen, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02215-4 · Cited by 297
“Among transport systems, liposomes—artificial vesicles composed of a lipid bilayer—are the most extensively studied, particularly for their applications in cancer therapy [165].”
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
Rodríguez, F., Caruana, P., De la Fuente, N., Español, P., Gámez, M., Balart, J., Llurba, E., Rovira, R., Ruiz, R., Martín-Lorente, C., et al. (2022) · Biomolecules · doi:10.3390/biom12060784 · Cited by 274
Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases
Deng, Y., Zhang, X., Shen, H., He, Q., Wu, Z., Liao, W., & Yuan, M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00489 · Cited by 259
Pande, S. (2023) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2023.2247036 · Cited by 258
Lipid-based nanoparticle formulations for small molecules and RNA drugs
Ickenstein, L. M., & Garidel, P. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1669558 · Cited by 193
Nanoparticles and siRNA: a new era in therapeutics?
Pérez-Carrión, M. D., Posadas, I., & Ceña, V. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107102 · Cited by 48
Qiu, M., Ouyang, J., Sun, H., Meng, F., Cheng, R., Zhang, J., Cheng, L., Lan, Q., Deng, C., & Zhong, Z. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b10533 · Cited by 45
Metadata
- Authors
- Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 68
- Issue
- 3
- Pages
- 701-787
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2464231245
- Cited by
- 744
- References
- 691
- FWCI
- 19.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.